Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Mucociliary ClearanceRecruiting Location: Western Australia
MRI for investigating airway clearance techniques in adults with cystic fibrosis , protocol number ACTRN12620001159943
We aim to investigate new techniques in magnetic resonance imaging (MRI) pre and post airway clearance techniques (ACT). Adults with CF will be invited to participate, and to perform their usual ACT (i.e. breathing exercises to clear mucus from their airways) within the MRI under the guidance of an experienced physiotherapist. This will allow for innovative cutting edge imaging to be performed before and after the ACT are performed, to provide information on airway structure and function; specifically in regard to the movement of mucous (sputum) and trapped air, and well as dynamic function of the larger airways.
Age:
18 Years and Older
Mutation(s):
Not specified
FEV1% Predicted:
Number of Visits:
Length of Participation:
OtherRecruiting Location: Queensland
Measuring antibiotic levels in people with cystic fibrosis taking treatment for mycobacterial lung infection. , protocol number ACTRN12619000948190
We will test the blood levels of important drugs given to patients with CF with NTM infection and compare to the drug levels in people without cystic fibrosis published in other studies. In this way we can help determine whether the doses we are using are correct or need to be changed. If the doses of antibiotics being used in CF are too low this could lead to new dosing regimens being used in future drug trials.
Restore CFTR FunctionEnrolling Location: Multiple care centres across the US
Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part A) , protocol number (Vertex VX20-445-111 Part A) NCT04537793
This study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.
2 Years to 5 Years
Two Copies F508del or One Copy F508del
No FEV1 Limit
5
53 days
Restore CFTR FunctionEnrolling Location: California, USA
Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part B) , protocol number VX20-445-111 PART B NCT04537793
9
32 weeks
ObservationalEnrolling Location: Multiple care centres across the US
Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor in children (PROMISE Pediatric Cohort) (PROMISE-OB-18 - Pediatric Cohort) , protocol number NCT04613128
This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in children with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects children with CF across many different aspects of the disease.
6 to 11 Years
6
2 Years
Anti-InfectiveEnrolling Location: Not specified
Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 SAD) , protocol number Armata Phase 1b/2 SAD NCT04596319
This study will look at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
No Mutation Requirement
60% or greater
8
29 days
Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 MAD) , protocol number Armata Phase 1b/2 MAD NCT04596319
10
31 days
OtherRecruiting Location: Germany & Israel
A Phase 2 Study to evaluate the safety, tolerability, PK and PD in cystic fibrosis patients with at least 1 G542X Allele , protocol number NCT04126473
This is a Phase 2 open label study to evaluate the safety, tolerability, PK and PD of multiple dose levels of SC administered ELX-02 in patients with CF with at least one G542X allelle.
16 Years and Older
40%
ObservationalRecruiting Location: Alfred Hospital, Victoria
Modified Release Posaconazole in patients with cystic fibrosis , protocol number NCT03421366
A prospective single centre observational cohort of patients with cystic fibrosis to determine whether adequate serum levels of posaconazole, after administration of the newer modified release once daily oral formation, can be achieved.
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part B) , protocol number NCT04509050
This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.
Less than 6 Years